Progression of disease after the most recent anticancer treatment. At least 1 prior chemotherapy regimen must have included a taxane.
Platinum-sensitive ovarian cancer defined by recurrence or progression of disease \> 6 AND \< 24 months after completion of the most recent platinum-based therapy.
Measurable disease as defined by RECIST 1.1.
ECOG performance status of 0 or 1.
Completion of all therapy for the treatment of cancer 2 weeks before the start of study therapy and recovered.
You may not be if
Evidence of platinum-refractory ovarian cancer defined as recurrence or progression during the first 6 cycles of or \< 6 months after the beginning of first-line platinum based chemotherapy.
Evidence of platinum-resistant ovarian cancer defined as recurrence or progression within 6 months after completing the most recent platinum-based therapy.
More than 3 prior lines of cytotoxic chemotherapy for ovarian cancer.
Prior malignancy (other than ovarian cancer), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥ 2 years or which will not limit survival to \< 2 years.
Breastfeeding and pregnant.
Known central nervous system metastases and/or carcinomatous meningitis.
Subjects with active cardiovascular disease not medically controlled or those who have had myocardial infarction in the past 6 months..
Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease, partial or complete bowel obstruction.
Clareo Health | Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)
